Back to results
US 2006/0135610 A1Published application
Cardiovascular compositions
OwnerJonathan Bortz, Mitchell Kirschner +2inventors
InventorsJonathan Bortz, Mitchell Kirschner, Marc Hermelin, David Hermelin
Life of this patent
Estimating the term…
Abstract
Compositions that promote and/or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and/or maintain cardiovascular health through the prevention, stabilization, reversal and/or treatment of coronary artery disease and/or cerebrovascular disease. Such compositions may be used independently to promote and/or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and/or a health deteriorating condition.
Claims96
A composition comprising:
- an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, to promote or maintain health.
2 more elements
A cardiovascular health promoting or maintaining composition comprising:
- an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, in one or more dosage forms.
2 more elements
A composition for treatment of a cardiovascular disease comprising:
- an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, in one or more dosage forms for treatment of a cardiovascular disease.
2 more elements
A cardiovascular health promoting or maintaining composition comprising:
- an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, in one or more dosage forms to prevent, stabilize, reverse or treat coronary artery disease or cerebrovascular disease.
2 more elements
A method of making a composition comprising:
- combining an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents and an effective amount of one or more platelet aggregation lowering agents;
- to promote or maintain health.
1 more element
A method of making a cardiovascular health promoting or maintaining composition comprising:
- combining an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, in one or more dosage forms.
2 more elements
A method of making a composition for treatment of a cardiovascular disease comprising:
- combining an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, in one or more dosage forms for treatment of a cardiovascular disease.
2 more elements
A method of making a cardiovascular health promoting or maintaining composition comprising:
- combining an effective amount of one or more endothelial cell anti-inflammatory agents;
- an effective amount of one or more nitric oxide generation promoting agents;
- an effective amount of one or more antioxidant agents;
- and
- an effective amount of one or more platelet aggregation lowering agents, in one or more dosage forms to prevent, stabilize, reverse or treatment coronary artery disease or cerebrovascular disease.
2 more elements
A composition comprising:
- at least 250 mg of at least one Omega-3 fatty acid, Omega-3 fatty acid derivative or a combination thereof;
- at least about 0.4 mg of folic acid, folate, folic acid derivative, folic acid metabolite, folate derivative, folate metabolite or a combination thereof;
- at least about 10 IU or an equivalent mg amount of at least one antioxidant;
- and
- at least about 12.5 mg of vitamin B6, an agent having Vitamin B6 functionality or a combination thereof, formulated in one or more dosage forms to be administered using consistent administration or intermittent administration .
2 more elements
A composition comprising:
- about 250 mg to about 1500 mg of at least one Omega-3 fatty acid, Omega-3 fatty acid derivative or a combination thereof;
- about 0.4 to about 5 mg of folic acid, folate, folic acid derivative, folate derivative, folic acid metabolite, folate metabolite or a combination thereof;
- about 10 IU to about 400 IU or equivalent mg amount of at least one antioxidant;
- and
- about 12.5 to about 100 mg of Vitamin B6, an agent having Vitamin B6 functionality or a combination thereof.
2 more elements
A composition comprising:
- at least one Omega-3 fatty acid, Omega-3 fatty acid derivative or a combination thereof in an amount of about 500 mg to about 3000 mg;
- at least one folic acid, folate, folic acid derivative, folate derivative, folic acid metabolite or folate metabolite in an amount of about 0.8 to about 10 mg;
- at least one antioxidant present in an amount of about 20 IU to about 800 IU;
- and
- Vitamin B6, an agent having Vitamin B6functionality or a combination thereof, present in an amount of about 25 mg to about 200 mg.
2 more elements
A composition comprising:
- about 750 mg to about 4500 mg of one or more Omega-3 fatty acids selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, alpha-linolenic acid and combinations thereof;
- about 1.2 mg to about 15 mg of folic acid, folate, folic acid derivative, folate derivative, folic acid metabolite, folate metabolite or a combination thereof;
- about 30 IU to about 1200 IU of one or more antioxidants;
- and
- about 37.5 mg to about 300 mg of Vitamin B6, an agent having Vitamin B6 functionality or a combination thereof.
2 more elements
A composition comprising:
- about 1000 mg to about 6000 mg of an Omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, alpha-linolenic acid and combinations thereof;
- about 1.6 mg to about 20 mg folic acid, folate, folic acid derivative, folate derivative, folic acid metabolite, folate metabolite or combinations thereof;
- about 40 IU to about 1600 IU of one or more antioxidants;
- and
- about 50 mg to about 400 mg Vitamin B6, an agent having Vitamin B6 functionality or a combination thereof.
2 more elements
A composition comprising:
- about 1250 mg to about 7500 mg of an Omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, alpha-linolenic acid and combinations thereof;
- about 2 mg to about 25 mg of folic acid, folate, folic acid derivative, folate derivative, folic acid metabolite, folate metabolite and combinations thereof;
- about 50 IU to about 2000 IU of one or more antioxidants;
- and
- about 67.5 mg to about 500 mg vitamin B6, an agent having Vitamin B6 functionality or a combination thereof.
2 more elements
A composition for promoting or maintaining cardiovascular health comprising:
- about 1000 mg of one or more Omega-3 fatty acids, about 300 IU of Vitamin E and about 70 mg Omega-6 fatty acids in two or more gel capsules;
- and
- about 4.0 mg of folic acid, about 37.5 mg of Vitamin B6, about 50 mg Vitamin C, about 1000 mg calcium, and about 800 IU Vitamin D in two or more tablets, caplets or capsules for administration to promote or maintain cardiovascular health.
A method for prevention, stabilization, reversal or treatment of coronary artery disease or cerebrovascular disease comprising:
- determining cardiovascular risk level of a human prior to administering a composition comprising an effective amount of at least one Omega-3 fatty acid or Omega-3 fatty acid derivative, an effective amount of folic acid or folate, an effective amount of one or more antioxidants and an effective amount of Vitamin B6, an agent having Vitamin B6 functionality or a combination thereof in a dosage formulation effective for said cardiovascular risk level.
A composition for prevention, stabilization, reversal or treatment of coronary artery disease and cerebrovascular disease comprising:
- at least 250 mg of at least one Omega-3 fatty acid or Omega-3 fatty acid derivative;
- at least about 0.4 mg of folic acid, folate, folic acid derivative, folate derivative, folic acid metabolite, folate metabolite or a combination thereof;
- at least about 10 IU or equivalent mg amount of at least one antioxidant;
- and
- at least about 12.5 mg of Vitamin B6, an agent having Vitamin B6functionality or a combination thereof, in one or more dosage forms for administration to humans of a very low cardiovascular risk level.
2 more elements
A method of packaging a composition comprising:
- packaging said composition in a container having indicia indicating dosage level dependent upon cardiovascular risk level of human.
A method of administering a composition comprising:
- administering a cardiovascular health promoting or maintaining composition dosage to a human or other animal and increasing said dosage or decreasing said dosage based on cardiovascular risk level of said human or other animal.
A method of administering a composition comprising:
- administering in one or more dosage forms about 250 mg to about 1500 mg of one or more endothelial cell anti-inflammatory agents to a human or other animal of very low cardiovascular risk;
- administering in one or more dosage forms about 500 mg to about 3000 mg of one or more endothelial cell anti-inflammatory agents to a human or other animal of low cardiovascular risk;
- administering in one or more dosage forms about 750 mg to about 4500 mg of one or more endothelial cell anti-inflammatory agents to a human or other animal of moderate cardiovascular risk;
- administering in one or more dosage forms about 1000 mg to about 6000 mg of one or more endothelial cell anti-inflammatory agents to a human or other animal of high cardiovascular risk;
- or
- administering in one or more dosage forms about 1250 mg to about 7500 mg of one or more endothelial cell anti-inflammatory agents to a human or other animal of very high cardiovascular risk;
- for prevention, stabilization, reversal or treatment of coronary artery disease or cerebrovascular disease.
4 more elements
A method of administering a composition comprising:
- administering in one or more dosage forms about 0.4 mg to about 5 mg of one or more nitric oxide generation promoting agents to a human or other animal of very low cardiovascular risk;
- administering in one or more dosage forms about 0.8 mg to about 10 mg of one or more nitric oxide generation promoting agents to a human or other animal of low cardiovascular risk;
- administering in one or more dosage forms about 1.2 mg to about 15 mg of one or more nitric oxide generation promoting agents to a human or other animal of moderate cardiovascular risk;
- administering in one or more dosage forms about 1.6 mg to about 20 mg of one or more nitric oxide generation promoting agents to a human or other animal of high cardiovascular risk;
- or
- administering in one or more dosage forms about 2 mg to about 25 mg of one or more nitric oxide generation promoting agents to a human or other animal of very high cardiovascular risk;
- for prevention, stabilization, reversal or treatment of coronary artery disease or cerebrovascular disease.
4 more elements
A method of administering a composition comprising:
- administering in one or more dosage forms about 10 IU to about 400 IU of one or more antioxidant agents to a human or other animal of very low cardiovascular risk;
- administering in one or more dosage forms about 20 IU to about 800 IU of one or more antioxidant agents to a human or other animal of low cardiovascular risk;
- administering in one or more dosage forms about 30 IU to about 1200 IU of one or more antioxidant agents to a human or other animal of moderate cardiovascular risk;
- administering in one or more dosage forms about 40 IU to about 1600 IU of one or more antioxidant agents to a human or other animal of high cardiovascular risk;
- or
- administering in one or more dosage forms about 50 IU to about 2000 IU of one or more antioxidant agents to a human or other animal of very high cardiovascular risk;
- for prevention, stabilization, reversal or treatment of coronary artery disease or cerebrovascular disease.
4 more elements
A method of administering a composition comprising:
- administering in one or more dosage forms about 12.5 mg to about 100 mg of one or more platelet aggregation lowering agents to a human or other animal of very low cardiovascular risk;
- administering in one or more dosage forms about 25 mg to about 200 mg of one or more platelet aggregation lowering agents to a human or other animal of low cardiovascular risk;
- administering in one or more dosage forms about 37.5 mg to about 300 mg of one or more platelet aggregation lowering agents to a human or other animal of moderate cardiovascular risk;
- administering in one or more dosage forms about 50 mg to about 400 mg of one or more platelet aggregation lowering agents to a human or other animal of high cardiovascular risk;
- or
- administering in one or more dosage forms about 67.5 mg to about 500 mg of one or more platelet aggregation lowering agents to a human or other animal of very high cardiovascular risk;
- for prevention, stabilization, reversal or treatment of coronary artery disease or cerebrovascular disease.
4 more elements
A method of administering a composition comprising:
- administering in one or more dosage forms about 250 mg to about 1500 mg of one or more endothelial cell anti-inflammatory agents and one or more agents selected from the group consisting of nitric oxide generation promoting agents, antioxidant agents and platelet aggregation lowering agents, to a human or other animal of very low cardiovascular risk;
- administering in one or more dosage forms about 500 mg to about 3000 mg of one or more endothelial cell anti-inflammatory agents and one or more agents selected from the group consisting of nitric oxide generation promoting agents, antioxidant agents and platelet aggregation lowering agents, to a human or other animal of low cardiovascular risk;
- administering in one or more dosage forms about 750 mg to about 4500 mg of one or more endothelial cell anti-inflammatory agents and one or more agents selected from the group consisting of nitric oxide generation promoting agents, antioxidant agents and platelet aggregation lowering agents, to a human or other animal of moderate cardiovascular risk;
- administering in one or more dosage forms about 1000 mg to about 6000 mg of one or more endothelial cell anti-inflammatory agents and one or more agents selected from the group consisting of nitric oxide generation promoting agents, antioxidant agents and platelet aggregation lowering agents, to a human or other animal of high cardiovascular risk;
- or
- administering in one or more dosage forms about 1250 mg to about 7500 mg of one or more endothelial cell anti-inflammatory agents and one or more agents selected from the group consisting of nitric oxide generation promoting agents, antioxidant agents and platelet aggregation lowering agents, to a human or other animal of very high cardiovascular risk;
- for prevention, stabilization, reversal or treatment of coronary artery disease or cerebrovascular disease.
4 more elements
Dependencies are inferred from the claim text.